Literature DB >> 8624192

Surgical aspects of patients with adenocarcinoma of the stomach operated on for cure.

J A Söreide1, J A van Heerden, L J Burgart, J H Donohue, M G Sarr, D M Ilstrup.   

Abstract

BACKGROUND: A retrospective study was performed to evaluate our recent results of curative gastric resections for adenocarcinoma.
METHODS: Between 1979 and 1988, 187 patients fulfilled study entry criteria. This group of patients composes 64% of all patients with tumors arising distal to the gastroesophageal junction. Tumors arising in the region of the gastroesophageal junction were excluded. Patients were classified according to the American Society of Anesthesiologists physical status classification ( > or = 3, 56%) and Eastern Cooperative Oncology Group performance status ( > or = 2, 44%). Histologic characteristics were re-reviewed.
INTERVENTIONS: Subtotal and total gastrectomies were performed in 78% and 22% of the patients, respectively. Extended lymph node dissections were performed selectively (5%). Adjuvant chemotherapy and radiotherapy were employed in 3% and 2% of patients, respectively.
RESULTS: Postoperative morbidity and mortality were 27% and 4%, respectively. Synchronous splenectomy (P = .06) and type of gastric resection (P = .06) showed a borderline association with postoperative complications, but did not affect postoperative mortality. With a median follow-up time of 47 months in all patients, and a median of 9 years in patients still alive, the 5- and 10-year overall survival rates (Kaplan-Meier method) were 48% and 32%, respectively. In univariate survival analysis, age, American Society of Anesthesiologists classification, stage, tumor diameter, serosal extension of tumor lymph node metastases, and type of resection showed prognostic significance. In the Cox multivariate analysis, however, only serosal extension of tumor (P < .001) and lymph node metastases (P = .02) were independent prognostic factors.
CONCLUSIONS: Despite the older age and comorbid conditions of patients with gastric cancer, 5-year survival was achieved in half the patients by standard radical operations. Until appropriate controlled prospective studies are performed, total gastrectomy, splenectomy, and extended lymph node dissection should not be routinely adopted, given their unproven efficacy and potentially increased morbidity and mortality.

Entities:  

Mesh:

Year:  1996        PMID: 8624192     DOI: 10.1001/archsurg.1996.01430170027003

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  9 in total

1.  DO PROXIMAL AND DISTAL GASTRIC TUMOURS BEHAVE DIFFERENTLY?

Authors:  Laurence Bedin da Costa; Marcelo Garcia Toneto; Luis Fernando Moreira
Journal:  Arq Bras Cir Dig       Date:  2016 Nov-Dec

2.  Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution.

Authors:  Steven C Cunningham; Farin Kamangar; Min P Kim; Sommer Hammoud; Raqeeb Haque; Anirban Maitra; Elizabeth Montgomery; Richard E Heitmiller; Michael A Choti; Keith D Lillemoe; John L Cameron; Charles J Yeo; Richard D Schulick
Journal:  J Gastrointest Surg       Date:  2005 May-Jun       Impact factor: 3.452

3.  Lymphoscintigraphy in detection of the regional lymph node involvement in gastric cancer.

Authors:  M Mahir Ozmen; Baris Zulfikaroglu; N Ozlem Kucuk; Necdet Ozalp; Gulseren Aras; Tankut Koseoglu; Mahmut Koç
Journal:  Ann R Coll Surg Engl       Date:  2006-11       Impact factor: 1.891

Review 4.  The relevance of gastrointestinal fistulae in clinical practice: a review.

Authors:  M Falconi; P Pederzoli
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

5.  Old and new TNM in carcinoma of the gastric antrum: analysis of our personal experience.

Authors:  Paolo Del Rio; Paolo Dell'Abate; Paolo Soliani; Maria Francesca Arcuri; Sara Tacci; Stefanie Ziegler; Mario Sianesi
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

6.  Poor prognosis of advanced gastric cancer with metastatic suprapancreatic lymph nodes.

Authors:  Toru Kusano; Norio Shiraishi; Hidefumi Shiroshita; Tsuyoshi Etoh; Masafumi Inomata; Seigo Kitano
Journal:  Ann Surg Oncol       Date:  2013-01-09       Impact factor: 5.344

7.  Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer.

Authors:  Zi-Yu Li; Fei Shan; Lian-Hai Zhang; Zhao-De Bu; Ai-Wen Wu; Xiao-Jiang Wu; Xiang-Long Zong; Qi Wu; Hui Ren; Jia-Fu Ji
Journal:  World J Surg Oncol       Date:  2011-09-26       Impact factor: 2.754

8.  Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.

Authors:  Stuart G Marcus; Daniel Cohen; Ke Lin; Kwok Wong; Scott Thompson; Adina Rothberger; Milan Potmesil; Spiros Hiotis; Elliot Newman
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

9.  Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30 years.

Authors:  Fausto Rosa; Sergio Alfieri; Antonio Pio Tortorelli; Claudio Fiorillo; Guido Costamagna; Giovanni Battista Doglietto
Journal:  World J Surg Oncol       Date:  2014-07-16       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.